Immuneering Corp SEC filings IMRX

Immuneering Corp has 322 filings in SEC EDGAR's recent list, going back to Oct 4, 2019. Its latest annual report, Form 10-K, was filed on Mar 6, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 29, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (results of operations). The company's fiscal year ends on December 31.

Immuneering Corp SEC filings
Form Description Filed Period
DEFA14A Additional proxy material Apr 20, 2026 —
DEF 14A Proxy statement Apr 20, 2026 Apr 20, 2026
DEFA14A Additional proxy material Apr 21, 2025 —
DEF 14A Proxy statement Apr 21, 2025 Apr 21, 2025
DEFA14A Additional proxy material Apr 23, 2024 —
DEF 14A Proxy statement Apr 23, 2024 Apr 23, 2024
DEFA14A Additional proxy material May 1, 2023 —
DEF 14A Proxy statement May 1, 2023 May 1, 2023
DEFA14A Additional proxy material May 2, 2022 —
DEF 14A Proxy statement May 2, 2022 Jun 21, 2022

Showing 10 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
IMRX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Cambridge, MA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1790340

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.